File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: High intensity focused ultrasound therapy: a new treatment on the horizon for hepatocellular carcinoma
  • Basic View
  • Metadata View
  • XML View
TitleHigh intensity focused ultrasound therapy: a new treatment on the horizon for hepatocellular carcinoma
 
AuthorsChan, A
Fan, ST
Cheung, TT
Poon, R
Lo, CM
 
KeywordsMedical sciences
Endocrinology
 
Issue Date2011
 
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
CitationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 451, abstract PP33-03 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
 
AbstractBACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and BACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and innovative loco-regional treatment for hepatocellular carcinoma (HCC) in recent years. It is an extracorporeal conformal therapy. By targeting a high intensity ultrasound beam at a focal point within the tumor, hyperthermia is induced leading to coagulation necrosis of the tumor cells. We herein report our experience in its clinical application for treatment of recurrent HCC. METHODS: From October 2006 to October 2009, 27 patients received HIFU therapy for recurrent HCC in our center. Their postoperative and survival outcomes were compared with 76 patients who received radiofrequency ablation (RFA) within the same period. P value < 0.05 was considered to be significant. RESULTS: The median age of patients receiving HIFU and RFA was 63 and 62 years old respectively. There was no difference in the frequency of co-morbid illness and hepatitis B positivity between the two groups. The median tumor size in HIFU and RFA group was 1.8 and 1.7 cm respectively (P = 0.28). Operative morbidity rate in the HIFU and RFA group was 7.4 and 22.4% respectively (P = 0.06). Skin burn and liver abscess were the two complications associated with HIFU therapy. There was no hospital mortality in the HIFU group while two deaths were observed in the RFA group. The 1-, 2- and 3-year tumor-free survival rates for HIFU group were 33.3, 22.2 and 0%, respectively, and for RFA group were 26.9, 0, 0%, respectively (P = 0.22). The 1-, 2- and 3-year overall survival rates for HIFU group were 100, 100 and 85.7%, respectively, and for RFA group were 89.1, 71.9 and 62.7%, respectively (P = 0.19). CONCLUSION: Our preliminary experience in utilizing HIFU therapy for treatment of recurrent HCC is promising. Further studies are needed to define its role as a primary treatment of HCC.
 
Descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
 
ISSN1936-0533
2013 Impact Factor: 2.468
 
DOIhttp://dx.doi.org/10.1007/s12072-010-9241-z
 
ISI Accession Number IDWOS:000300105300001
 
DC FieldValue
dc.contributor.authorChan, A
 
dc.contributor.authorFan, ST
 
dc.contributor.authorCheung, TT
 
dc.contributor.authorPoon, R
 
dc.contributor.authorLo, CM
 
dc.date.accessioned2011-07-27T02:02:44Z
 
dc.date.available2011-07-27T02:02:44Z
 
dc.date.issued2011
 
dc.description.abstractBACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and BACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and innovative loco-regional treatment for hepatocellular carcinoma (HCC) in recent years. It is an extracorporeal conformal therapy. By targeting a high intensity ultrasound beam at a focal point within the tumor, hyperthermia is induced leading to coagulation necrosis of the tumor cells. We herein report our experience in its clinical application for treatment of recurrent HCC. METHODS: From October 2006 to October 2009, 27 patients received HIFU therapy for recurrent HCC in our center. Their postoperative and survival outcomes were compared with 76 patients who received radiofrequency ablation (RFA) within the same period. P value < 0.05 was considered to be significant. RESULTS: The median age of patients receiving HIFU and RFA was 63 and 62 years old respectively. There was no difference in the frequency of co-morbid illness and hepatitis B positivity between the two groups. The median tumor size in HIFU and RFA group was 1.8 and 1.7 cm respectively (P = 0.28). Operative morbidity rate in the HIFU and RFA group was 7.4 and 22.4% respectively (P = 0.06). Skin burn and liver abscess were the two complications associated with HIFU therapy. There was no hospital mortality in the HIFU group while two deaths were observed in the RFA group. The 1-, 2- and 3-year tumor-free survival rates for HIFU group were 33.3, 22.2 and 0%, respectively, and for RFA group were 26.9, 0, 0%, respectively (P = 0.22). The 1-, 2- and 3-year overall survival rates for HIFU group were 100, 100 and 85.7%, respectively, and for RFA group were 89.1, 71.9 and 62.7%, respectively (P = 0.19). CONCLUSION: Our preliminary experience in utilizing HIFU therapy for treatment of recurrent HCC is promising. Further studies are needed to define its role as a primary treatment of HCC.
 
dc.descriptionpp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
 
dc.description.otherThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 451, abstract PP33-03
 
dc.identifier.citationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 451, abstract PP33-03 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
 
dc.identifier.doihttp://dx.doi.org/10.1007/s12072-010-9241-z
 
dc.identifier.epage451
 
dc.identifier.hkuros188339
 
dc.identifier.isiWOS:000300105300001
 
dc.identifier.issn1936-0533
2013 Impact Factor: 2.468
 
dc.identifier.issue1
 
dc.identifier.spage451
 
dc.identifier.urihttp://hdl.handle.net/10722/136095
 
dc.identifier.volume5
 
dc.languageeng
 
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
dc.publisher.placeUnited States
 
dc.relation.ispartofHepatology International
 
dc.rightsThe original publication is available at www.springerlink.com
 
dc.subjectMedical sciences
 
dc.subjectEndocrinology
 
dc.titleHigh intensity focused ultrasound therapy: a new treatment on the horizon for hepatocellular carcinoma
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chan, A</contributor.author>
<contributor.author>Fan, ST</contributor.author>
<contributor.author>Cheung, TT</contributor.author>
<contributor.author>Poon, R</contributor.author>
<contributor.author>Lo, CM</contributor.author>
<date.accessioned>2011-07-27T02:02:44Z</date.accessioned>
<date.available>2011-07-27T02:02:44Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 451, abstract PP33-03</identifier.citation>
<identifier.issn>1936-0533</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/136095</identifier.uri>
<description>pp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011</description>
<description.abstract>BACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and BACKGROUND: High intensity focused ultrasound (HIFU) therapy has emerged to be a new and innovative loco-regional treatment for hepatocellular carcinoma (HCC) in recent years. It is an extracorporeal conformal therapy. By targeting a high intensity ultrasound beam at a focal point within the tumor, hyperthermia is induced leading to coagulation necrosis of the tumor cells. We herein report our experience in its clinical application for treatment of recurrent HCC. METHODS: From October 2006 to October 2009, 27 patients received HIFU therapy for recurrent HCC in our center. Their postoperative and survival outcomes were compared with 76 patients who received radiofrequency ablation (RFA) within the same period. P value &lt; 0.05 was considered to be significant. RESULTS: The median age of patients receiving HIFU and RFA was 63 and 62 years old respectively. There was no difference in the frequency of co-morbid illness and hepatitis B positivity between the two groups. The median tumor size in HIFU and RFA group was 1.8 and 1.7 cm respectively (P = 0.28). Operative morbidity rate in the HIFU and RFA group was 7.4 and 22.4% respectively (P = 0.06). Skin burn and liver abscess were the two complications associated with HIFU therapy. There was no hospital mortality in the HIFU group while two deaths were observed in the RFA group. The 1-, 2- and 3-year tumor-free survival rates for HIFU group were 33.3, 22.2 and 0%, respectively, and for RFA group were 26.9, 0, 0%, respectively (P = 0.22). The 1-, 2- and 3-year overall survival rates for HIFU group were 100, 100 and 85.7%, respectively, and for RFA group were 89.1, 71.9 and 62.7%, respectively (P = 0.19). CONCLUSION: Our preliminary experience in utilizing HIFU therapy for treatment of recurrent HCC is promising. Further studies are needed to define its role as a primary treatment of HCC.</description.abstract>
<language>eng</language>
<publisher>Springer New York LLC. The Journal&apos;s web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0</publisher>
<relation.ispartof>Hepatology International</relation.ispartof>
<rights>The original publication is available at www.springerlink.com</rights>
<subject>Medical sciences</subject>
<subject>Endocrinology</subject>
<title>High intensity focused ultrasound therapy: a new treatment on the horizon for hepatocellular carcinoma</title>
<type>Conference_Paper</type>
<identifier.doi>10.1007/s12072-010-9241-z</identifier.doi>
<identifier.hkuros>188339</identifier.hkuros>
<identifier.volume>5</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>451</identifier.spage>
<identifier.epage>451</identifier.epage>
<identifier.isi>WOS:000300105300001</identifier.isi>
<publisher.place>United States</publisher.place>
<description.other>The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 451, abstract PP33-03</description.other>
</item>